Big Pharma Earnings Watch: Amgen, Eli Lilly, Merck and Pfizer

Four More Rx Giants Complete the Sweep, Beat Q2 Earnings Forecasts After Hiking Prices


Over the past week, CSRxP has been tracking Q2 earnings for the biggest prescription drug manufacturers in the world. Yesterday, four more of these Big Pharma giants – Amgen, Eli Lilly, Merck and Pfizer – completed the sweep by reporting better-than-expected earnings between April and June.

How do Big Pharma giants like these continue to outpace earnings forecasts and keep the gravy train running while Americans are struggling to afford their medications? By price gouging patients to protect their bottom line. Here are just a few examples:
In total, all 12 Big Pharma giants that CSRxP tracked surpassed Q2 earnings expectations, all while raising prices in 2019. Big Pharma continues to thumb its nose at the crisis of affordability for prescription drugs. Washington simply must act to crack down on the industry’s egregious pricing practices and anti-competitive behavior in order to lower prices for American patients.

Read more on other Big Pharma companies’ Q2 earnings and price-gouging here: AbbVie and Sanofi; Bristol-Myers Squibb, AstraZeneca and Roche; GlaxoSmithKline (GSK); Novartis; Johnson & Johnson.


Sign-up for updates

  • This field is for validation purposes and should be left unchanged.